drugset / Trial / NCT02189317

Liposomal Bupivacaine for Pain Control Following Anterior Cruciate Ligament Reconstruction

NCT02189317 ↗

Phase 4 Completed 50 enrolled Emory University
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will consist of 80 patients ages 18 to 50 at the Emory Orthopaedic and Spine Center who are undergoing Anterior Cruciate Ligament (ACL) reconstruction with a quadriceps tendon autograft or bone patellar tendon bone autograft by Dr. Karas or Dr. Xerogeanes. Patients will be randomized into treatment and control arms. The treatment arm will include 40 patients receiving liposomal bupivacaine intra-operatively in addition to the current standard pain control regimen. The control group will include 40 patients receiving the standard post-operative pain control regimen. Patients will be assessed to identify differences in post-operative pain, satisfaction, as well as concomitant pain medication use. Post-operative range of motion will also be assessed.

Timeline

Start
2014-08
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 1.3 % Other
Subject Bupivacaine Other / unclassified 20 ml Other

Indications

No indication recorded.